Shanghai Fosun Long March Medical Science struck a deal to bring the Nu.Q(TM) diagnostic platform developed by Belgium’s VolitionRx to China. The two companies have already started a China clinical trial of a lung cancer diagnostic as the first application. Fosun Long March is the investment platform of the in-vitro diagnostics division of Fosun Pharma. In a China trial expected to be completed this year, Fosun Long March is collecting and testing blood samples using Volition’s Nu.Q assays.
Source: China Biotoday
